Skip to main content
hero background ribbon

Our Pipeline

We are developing single-course gene editing medicines to disrupt today’s standard of care for cardiovascular disease. 

 

See Our Pipeline
Verve Scientist Verve team meeting Test tubes

Our Therapeutic Vision

Verve is taking a stepwise approach to clinical development with our single-course gene editing programs.

Our Pipeline

Verve is advancing a pipeline of single-course in vivo gene editing programs intended to safely turn off genes in the liver that contribute to ASCVD risk. Our initial programs target the PCSK9, ANGPTL3 and LPA genes, which have been validated via human genetics and human pharmacology as targets for lowering blood lipid levels. We envision expanding beyond these programs to develop a suite of single-course gene editing medicines that could address additional independent causes of ASCVD in the future.

ProgramIndicationsTechnologyResearchInd-enablingClinicalRights
PCSK9
(VERVE-101)
Indications
Heterozygous familial hypercholesterolemia (HeFH)
ASCVD
Technology
Base Editor
Development Status
Clinical
Verve logoLilly logo
PCSK9
(VERVE-102)
Indications
Heterozygous familial hypercholesterolemia (HeFH)
ASCVD
Technology
Base Editor
Development Status
IND-Enabling
Verve logoLilly logo
ANGPTL3
(VERVE-201)
Indications
Homozygous familial hypercholesterolemia (HoFH)
Refractory hypercholesterolemia
Technology
Base Editor
Development Status
IND-Enabling
Verve logoLilly logo
LPA
Indications
ASCVD with High Lp(a)
Technology
Novel Editor
Development Status
Research
Verve logoLilly logo
Undisclosed
Indications
Undisclosed ASCVD
Technology
Base Editor
Development Status
Research
Verve logoLilly logo
Undisclosed
Indications
Undisclosed liver disease
Technology
Novel Editor
Development Status
Research
Verve logoVertex logo